Dr Jeroen Van Dorp speaks to ecancer in an online interview for the virtual ESMO 2021 meeting about cohort 2 of the NABUCCO trial of high- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer.

He explains that this study aims to provide other treatment options for patients who are unsuitable for cisplatin-based chemotherapy, and outlines the adjustments made for cohort 2.

Dr Van Dorp reports their findings, noting the differences in these results when compared to similar studies in other cancer types. He concludes by discussing potential follow-on research.